Replies to post #92074 on Biotech Values

[ghmm]

There isn't a lot of room south of medicore :-).

As DD has pointed out Dan Welch did a nice job forcing Roche to stick with 191 or pay up to move on. I think that if the safety data in the low doses is good (little to no grade 3-4 AE's particularly in the lower dose) that the boosted studies goes forward and the drug has some life.